EG-501

· Evergreen Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for EG-501, covering 2025-12-15 to 2025-12-15. Get the full timeline:

Most recent: Clinical Trial Update: EG-501 for Cognitive Impairment in Neuropsychiatric SLE (NPSLE): Efficacy and Safety Study [Phase 2]